Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO.

Evangelos Terpos,Meletios A. Dimopoulos,Mario Boccadoro,Sosana Delimpasi,Meral Beksac,Eirini Katodritou,Philippe Moreau,Luca Baldini,Argiris Symeonidis,Jelena Bila,Albert Oriol,Maria-Victoria Mateos,Hermann Einsele,Ioannis Orfanidis,Katharine S. Gries,John Fastenau,Tobias Kampfenkel,Yanping Qiu,Himal Amin,Pieter Sonneveld

Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO.

2021

8046Background: APOLLO (NCT03180736) is a phase 3 trial of pomalidomide and dexamethasone (Pd) ± subcutaneous daratumumab (1800 mg, co-formulated with recombinant human hyaluronidase PH20 in 15 mL)...

Keywords:

Medicine
Internal medicine
Recombinant Human Hyaluronidase
health related quality of life
Oncology
Pomalidomide
in patient
Daratumumab
relapsed refractory
Dexamethasone
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations